相关实验视频

Updated: Jul 17, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

透露转移性割耐药前列腺癌主调节器通过 lncRNAs 中心的调节网络

Rafaella Sousa Ferraz¹, João Vitor Ferreira Cavalcante², Leandro Magalhães¹

¹Laboratory of Human and Medical Genetics, Institute of Biological Sciences, Federal University of Para, Belem, Brazil.

Cancer medicine

|August 30, 2023

概括

这项研究确定了调节转移性割抵抗性前列腺癌 (mCRPC) 的关键非编码RNA (ncRNA). SNHG18和HELLPAR显示出作为mCRPC的诊断生物标志物的潜力,提供新的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

转移性割抵抗性前列腺癌 (mCRPC) 是一种由雄激素受体 (AR) 轴驱动的侵袭性恶性瘤,即使在雄激素剥夺疗法 (ADT) 后也是如此.
非编码RNAs (ncRNAs) 在癌症进展中发挥关键作用,包括前列腺癌 (PCa),通过影响AR信号,增殖和割抵抗.

研究的目的:

在mCRPC中重建长非编码RNA (lncRNA) 中心的调节网络.
确定在mCRPC发育和进展中作为主调节剂 (MRs) 的 lncRNA.

主要方法:

利用公开可用的RNA测序数据推断mCRPC中的lncRNA调控网络.
应用主调节器分析使用五个基因签名,其次是功能丰富和象征回归建模.
在mCRPC中评估了 lncRNAs 的预测能力和作为生物标志物的潜力.

主要成果:

确定了31个涉及细胞增殖,瘤代谢和入侵转移级联的lncRNAs.
突出显示了SNHG18和HELLPAR作为重要的发现;SNHG18在mCRPC下调并与转移和上皮-介质细胞转变 (EMT) 相关.
SNHG18和HELLPAR在区分mCRPC和初级割抵抗性前列腺癌 (CRPC) 与正常组织方面表现出强大的潜力.

结论:

这项研究增强了对mCRPC中lncRNA调节机制的理解.
已确定SNHG18和HELLPAR是主调节剂,也是mCRPC的有希望的新型诊断标.

关键词:

长非编码RNA是什么意思 mCRPC 的使用情况.系统生物学系统生物学转录网络重建的重建

更多相关视频

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

相关概念视频

Master Transcription Regulators

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...